Thomas Zilli (@zillithomas) 's Twitter Profile
Thomas Zilli

@zillithomas

Radiation Oncology, IOSI - Oncology Institute of Southern Switzerland, EOC, Switzerland

ID: 1041422567393959938

calendar_today16-09-2018 20:24:23

2,2K Tweet

1,1K Followers

964 Following

Matthias Guckenberger (@mat_guc) 's Twitter Profile Photo

Compliance to MDT recs in OMD pts: 👉83.7% of MDT recommendations correctly implemented 👉Reasons for major deviations: physician decision, patient comorbidity or patient decision. 👉Major deviations associated with more than one distant met and worse OS doi.org/10.1016/j.ctro…

Compliance to MDT recs in OMD pts:
👉83.7% of MDT recommendations correctly implemented
👉Reasons for major deviations: physician decision, patient comorbidity or patient decision.
👉Major deviations associated with more than one distant met and worse OS
doi.org/10.1016/j.ctro…
Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

🔥A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no ADT, 6-month ADT, or 24-month ADT after postoperative radiotherapy. ✅492 patients ✅10 years, 80% (no ADT), 77% (6-month

🔥A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no ADT, 6-month ADT, or 24-month ADT after postoperative radiotherapy. 

✅492 patients

✅10 years, 80% (no ADT), 77% (6-month
Ente Ospedaliero Cantonale (@enteospedaliero) 's Twitter Profile Photo

3 Ottobre, Lugano LAC – 1° Workshop di Genetica Oncologica in Ticino Per iscrizioni eventi.eoc.ch/oncogenetica/ Esperti svizzeri discuteranno la gestione dei pazienti a rischio genetico e familiare per carcinoma prostatico, renale e mammario. Supportato da SAKK

3 Ottobre, Lugano LAC – 1° Workshop di Genetica Oncologica in Ticino

Per iscrizioni eventi.eoc.ch/oncogenetica/

Esperti svizzeri discuteranno la gestione dei pazienti a rischio genetico e familiare per carcinoma prostatico, renale e mammario.
Supportato da <a href="/SAKK_ch/">SAKK</a>
European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

You’re still eligible for the 40% discount! Sign up now + collect CME credits at #EMUC24! Register now 👉 emuc.org/how-to-registe… ✅13 Plenary Sessions ✅EAU Section of Urological Imaging meeting ✅Special guest lecture ✅ESUP Symposium ✅FALCON workshop ESMO - Eur. Oncology ESTRO

You’re still eligible for the 40% discount! Sign up now + collect CME credits at #EMUC24! 

Register now 👉 emuc.org/how-to-registe… 

✅13 Plenary Sessions
✅EAU Section of Urological Imaging meeting
✅Special guest lecture
✅ESUP Symposium
✅FALCON workshop

<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/ESTRO_RT/">ESTRO</a>
Thomas Zilli (@zillithomas) 's Twitter Profile Photo

8 Gy single fx liver RT + BSC improves liver pain control compared to BSC in painful hepatic cancer: the CCTG HE1 trial thelancet.com/journals/lanon…

tombal (@bertrandtombal) 's Twitter Profile Photo

The endless debate in patients with BCR after radical treatment: Do Not EMBARK on When, If the Answer Is How | Journal of Clinical Oncology . ascopubs.org/doi/10.1200/JC… Gianluca Giannarini

Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com

Just in <a href="/TheLancetOncol/">The Lancet Oncology</a> 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian <a href="/KidneyCancerDoc/">Brian Shuch, MD</a> et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 <a href="/morr316/">Michael Morris</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/urotoday/">UroToday.com</a>
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer #BladderCancer BJU International bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

⚡️ Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer 

#BladderCancer <a href="/BJUIjournal/">BJU International</a> 

bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…
Nicholas van As (@nickva1) 's Twitter Profile Photo

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun TolanAlison Tree 💙⁩ ⁦Clive PeedellDr. Andrew Loblaw⁩ ⁦Prof Emma HallProf Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦<a href="/DrTolan/">Dr Shaun Tolan</a>⁩ <a href="/alison_tree/">Alison Tree 💙</a>⁩ ⁦<a href="/cpeedell/">Clive Peedell</a>⁩ <a href="/DrAndrewLoblaw/">Dr. Andrew Loblaw</a>⁩ ⁦<a href="/EmmaHall71/">Prof Emma Hall</a>⁩ <a href="/ProfJOSullivan/">Prof Joe O'Sullivan</a>⁩ authors.elsevier.com/sd/article/S03…
NEJM (@nejm) 's Twitter Profile Photo

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24
Dr. Denise Bernhardt (@drdbernhardt) 's Twitter Profile Photo

RADIO Trial: Another point for weekly cisplatin + RT in HPV+ LASCCHN: •Hearing impairment (>grade 2) at 1 year: 40.8% (weekly) vs 64.0% (q3weekly) (p=0.027) 👂🧏 •Tinnitus: 73.5% (weekly) vs 92.0% (q3weekly) 🔔 #ESMO2024 #radiotherapy

RADIO Trial: 
Another point for weekly cisplatin + RT in HPV+ LASCCHN:
•Hearing impairment (&gt;grade 2) at 1 year: 40.8% (weekly) vs 64.0% (q3weekly) (p=0.027) 👂🧏
•Tinnitus: 73.5% (weekly) vs 92.0% (q3weekly) 🔔

#ESMO2024 #radiotherapy
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

PFS and OS advantage of radium-223 + Enza vs Enza alone in metastatic prostate cancer—-new combo on the horizon —congrats silke gillessen and PEACE-3 team. No increased SREs! ESMO - Eur. Oncology #ESMO2024

PFS and OS advantage of radium-223 + Enza vs Enza alone in metastatic prostate cancer—-new combo on the horizon —congrats <a href="/Silke_Gillessen/">silke gillessen</a> and PEACE-3 team. No increased SREs! <a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMO2024
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com

Outstanding talk from <a href="/Silke_Gillessen/">silke gillessen</a> elegantly presenting PEACE-3 phase 3 trials first results. 

Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 <a href="/myESMO/">ESMO - Eur. Oncology</a> 

<a href="/OncoAlert/">OncoAlert</a> <a href="/urotoday/">UroToday.com</a>
Thomas Zilli (@zillithomas) 's Twitter Profile Photo

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial - The Lancet thelancet.com/journals/lance…

Pierre Blanchard, MD (@pblanchardmd) 's Twitter Profile Photo

Major congrats to my friend Dr Sofia Rivera on the HypoG-01 just presented at #ESMO2024 Hypofractionation not inferior to conventional fractionation for #BreastCancer with nodal RT. ✅Similar toxicity ✅Similar efficacy (BCSM OS LRFS DMFS) 3 weeks is the way to go!

Major congrats to my friend Dr Sofia Rivera on the HypoG-01 just presented at #ESMO2024

Hypofractionation not inferior to conventional fractionation for #BreastCancer with nodal RT.

✅Similar toxicity
✅Similar efficacy (BCSM OS LRFS DMFS)

3 weeks is the way to go!
Tom Powles (@tompowles1) 's Twitter Profile Photo

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Perioperative durvalumab + neoadjuvant chemo &amp; cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024  <a href="/NEJM/">NEJM</a>
Pierre Blanchard, MD (@pblanchardmd) 's Twitter Profile Photo

Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024

Transdermal estradiol as a new option for testosterone lowering vs LHRHa :

similar MFS &amp; OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...)

Open Qs:
1. efficacy vs antagonists
2. combination with other drugs (ARPI, PARPi) or RT

#ESMO2024
Ursula Vogl (@ursulavogl) 's Twitter Profile Photo

Prof Silke Gillessen silke gillessen presenting at #ESMO24 the results of stampede Arm K. Addition of Metformin has a clear benefit on metabolic effects on the long term. Look into the high volume subgroup outcomes in detail, interesting results!

Prof Silke Gillessen <a href="/Silke_Gillessen/">silke gillessen</a> presenting at #ESMO24 the results of stampede Arm K. Addition of Metformin has a clear benefit on metabolic effects on the long term. Look into the high volume subgroup outcomes in detail, interesting results!
Dr. Andrew Loblaw (@drandrewloblaw) 's Twitter Profile Photo

Thomas Kennedy leads 10y prostate #SBRT outcomes from 3 different prospective studies now epub at #RedJ IJROBP - The Red Journal doi.org/10.1016/j.ijro… Great biochemical control to 15 years and only 1% chance of mets! Note 10% of UIR pts received ADT and none had whole pelvic RT (-> #PR24)

Thomas Kennedy leads 10y prostate #SBRT outcomes from 3 different prospective studies now epub at #RedJ <a href="/IJROBP/">IJROBP - The Red Journal</a> 

doi.org/10.1016/j.ijro…

Great biochemical control to 15 years and only 1% chance of mets!  Note 10% of UIR pts received ADT and none had whole pelvic RT (-&gt; #PR24)
Amar Kishan (@amarukishan) 's Twitter Profile Photo

Pleased to share the newest MARCAP publication, out in European Urology -- the TRANSPORT analysis of T recovery after ADT for localized PCa, led by Wee Loon Ong and Tahmineh Romero Free share link: authors.elsevier.com/a/1joOX14kplyz…